交易 NRx Pharmaceuticals, Inc. - NRXP CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
价差 | - | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.025457% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.003235% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
---|
NRx Pharmaceuticals, Inc. Events
时间(协调世界时) (UTC) | 国家/地区 | 事件 |
---|---|---|
Tuesday, July 18, 2023 | ||
时间(协调世界时) (UTC) 15:00 | 国家/地区 US
| 事件 NRX Pharmaceuticals Inc Annual Shareholders Meeting NRX Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
Monday, August 14, 2023 | ||
时间(协调世界时) (UTC) 12:30 | 国家/地区 US
| 事件 Q2 2023 NRX Pharmaceuticals Inc Earnings Release Q2 2023 NRX Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Monday, November 13, 2023 | ||
时间(协调世界时) (UTC) 13:30 | 国家/地区 US
| 事件 Q3 2023 NRX Pharmaceuticals Inc Earnings Release Q3 2023 NRX Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 44.335 | 115.675 | 0.55534 | 0.71319 | 1.0065 |
销售/一般/行政费用,总计 | 27.308 | 74.944 | 0.90741 | 0.71319 | 1.0065 |
营业收入 | -44.335 | -115.675 | -0.55534 | -0.71319 | -1.0065 |
利息收入(费用),非经营净值 | 0.504 | 1.674 | -0.51633 | 1.20582 | 1.08892 |
税前净收入 | -39.754 | -93.063 | -1.07167 | 0.49263 | 0.08241 |
税后净收入 | -39.754 | -93.063 | -1.08951 | 0.40843 | 0.0661 |
未计算非常项目前的净收益 | -39.754 | -93.063 | -1.08951 | 0.40843 | 0.0661 |
净收入 | -39.754 | -93.063 | -1.08951 | 0.40843 | 0.0661 |
普通股股东可获收益 (不含非经常性项目) | -39.754 | -348.885 | -1.08951 | 0.40843 | 0.0661 |
普通股股东可获收益 (含非經常性項目) | -39.754 | -348.885 | -1.08951 | 0.40843 | 0.0661 |
摊薄净收入 | -39.754 | -348.885 | -1.08951 | 0.40843 | 0.0661 |
摊薄后加权平均股 | 65.7668 | 46.9177 | 2.73626 | 5.08836 | 8.92497 |
扣除特别项目的每股摊薄盈利 | -0.60447 | -7.43611 | -0.39818 | 0.08027 | 0.00741 |
Dividends per Share - Common Stock Primary Issue | |||||
每股正常摊薄盈利 | -0.60447 | -6.98329 | -0.48181 | 0.08027 | 0.00741 |
异常费用(收入) | 0 | 21.245 | -0.35207 | ||
研究与开发 | 17.027 | 20.257 | |||
Other Operating Expenses, Total | 0 | -0.771 | |||
其他,净值 | 4.077 | 20.938 | |||
Total Adjustments to Net Income | 0 | -255.822 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 9.435 | 9.888 | 9.141 | 9.6 | 15.705 |
销售/一般/行政费用,总计 | 5.785 | 5.432 | 5.012 | 6.642 | 10.222 |
研究与开发 | 3.65 | 4.456 | 4.129 | 2.958 | 5.483 |
异常费用(收入) | 0 | 0 | 0 | 0 | |
Other Operating Expenses, Total | 0 | 0 | 0 | 0 | |
营业收入 | -9.435 | -9.888 | -9.141 | -9.6 | -15.705 |
利息收入(费用),非经营净值 | 0.168 | 0.152 | 0.058 | 0.139 | 0.154 |
其他,净值 | -1.772 | -0.505 | 0 | 2.479 | 2.103 |
税前净收入 | -11.039 | -10.241 | -9.083 | -6.982 | -13.448 |
税后净收入 | -11.039 | -10.241 | -9.083 | -6.982 | -13.448 |
未计算非常项目前的净收益 | -11.039 | -10.241 | -9.083 | -6.982 | -13.448 |
净收入 | -11.039 | -10.241 | -9.083 | -6.982 | -13.448 |
Total Adjustments to Net Income | 0 | ||||
普通股股东可获收益 (不含非经常性项目) | -11.039 | -10.241 | -9.083 | -6.982 | -13.448 |
普通股股东可获收益 (含非經常性項目) | -11.039 | -10.241 | -9.083 | -6.982 | -13.448 |
摊薄净收入 | -11.039 | -10.241 | -9.083 | -6.982 | -13.448 |
摊薄后加权平均股 | 67.4539 | 66.4699 | 66.4496 | 65.7323 | 63.6675 |
扣除特别项目的每股摊薄盈利 | -0.16365 | -0.15407 | -0.13669 | -0.10622 | -0.21122 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.16365 | -0.15407 | -0.13669 | -0.10622 | -0.21122 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流动资产总额 | 25.795 | 32.714 | 0.08246 | 0.06949 | 0.03019 |
现金和短期投资 | 20.054 | 27.605 | 0.00047 | 0.00001 | 0.01108 |
Cash | 20.054 | 27.605 | 0.00047 | 0.00001 | 0.01108 |
Prepaid Expenses | 5.734 | 5.109 | 0.08199 | 0.06948 | 0.01911 |
Total Assets | 25.816 | 32.729 | 6.05041 | 32.0747 | 70.7962 |
Long Term Investments | 5.96795 | 32.0052 | 70.766 | ||
Total Current Liabilities | 15.585 | 11.923 | 0.60951 | 0.62244 | 0.56741 |
Payable/Accrued | 0.60951 | 0.62244 | 0.5511 | ||
Accrued Expenses | 4.513 | 1.632 | 0 | ||
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 18.407 | 11.923 | 3.93664 | 2.57421 | 1.25741 |
Total Long Term Debt | 2.822 | 0 | 2.67204 | 1.95176 | 0.69 |
Total Equity | 7.409 | 20.806 | 2.11376 | 29.5005 | 69.5387 |
Common Stock | 0.067 | 0.059 | 0.00269 | 24.5033 | 64.5415 |
Additional Paid-In Capital | 230.339 | 203.99 | 2.83109 | 4.62766 | 5.03621 |
Retained Earnings (Accumulated Deficit) | -222.997 | -183.243 | -0.72002 | 0.3695 | -0.03893 |
Total Liabilities & Shareholders’ Equity | 25.816 | 32.729 | 6.05041 | 32.0747 | 70.7962 |
Total Common Shares Outstanding | 66.443 | 58.8106 | 2.68824 | 5.14975 | 9.0355 |
Other Current Liabilities, Total | 1.293 | 6.086 | 0 | 0.01631 | |
Long Term Debt | 2.822 | 2.67204 | 1.95176 | 0.69 | |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Other Liabilities, Total | 0.6551 | ||||
Other Current Assets, Total | 0.007 | 0 | |||
Other Long Term Assets, Total | 0.021 | 0.015 | |||
Accounts Payable | 2.076 | 3.687 | |||
Current Port. of LT Debt/Capital Leases | 7.703 | 0.518 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 21.756 | 25.795 | 24.801 | 32.414 | 43.584 |
现金和短期投资 | 16.506 | 20.054 | 18.249 | 24.548 | 40.202 |
Cash | 16.506 | 20.054 | 18.249 | 24.548 | 40.202 |
Prepaid Expenses | 5.244 | 5.734 | 6.005 | 7.312 | 3.382 |
Total Assets | 21.78 | 25.816 | 24.824 | 32.433 | 43.601 |
Long Term Investments | |||||
Total Current Liabilities | 22.064 | 15.585 | 8.042 | 7.081 | 11.912 |
Payable/Accrued | |||||
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 22.064 | 18.407 | 8.042 | 7.081 | 11.912 |
Total Long Term Debt | 0 | 2.822 | 0 | 0 | 0 |
Long Term Debt | 0 | 2.822 | |||
Other Liabilities, Total | |||||
Total Equity | -0.284 | 7.409 | 16.782 | 25.352 | 31.689 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | |||
Common Stock | 0.07 | 0.067 | 0.068 | 0.067 | 0.067 |
Additional Paid-In Capital | 233.576 | 230.339 | 229.47 | 228.958 | 228.313 |
Retained Earnings (Accumulated Deficit) | -234.036 | -222.997 | -212.756 | -203.673 | -196.691 |
Total Liabilities & Shareholders’ Equity | 21.78 | 25.816 | 24.824 | 32.433 | 43.601 |
Total Common Shares Outstanding | 70.3097 | 66.443 | 67.6413 | 66.6413 | 66.6413 |
应收账款总额,净额 | |||||
Accounts Receivable - Trade, Net | |||||
Other Current Assets, Total | 0.006 | 0.007 | 0.547 | 0.554 | |
Other Long Term Assets, Total | 0.024 | 0.021 | 0.023 | 0.019 | 0.017 |
Accounts Payable | 3.776 | 2.076 | 2.168 | 3.078 | 4.311 |
Accrued Expenses | 4.797 | 4.513 | 4.803 | 3.146 | 2.947 |
Current Port. of LT Debt/Capital Leases | 12.189 | 7.703 | 0 | 0 | 0.52 |
Other Current Liabilities, Total | 1.302 | 1.293 | 1.071 | 0.857 | 4.134 |
Other Equity, Total | 0.106 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -39.754 | -93.063 | -1.08951 | 0.40843 | 0.0661 |
经营活动产生的现金 | -39.755 | -37.703 | -0.59862 | -0.79273 | -0.47319 |
非现金物品 | -0.704 | 60.256 | 0.30303 | 0 | |
营运资金的变化 | 0.699 | -4.898 | 0.18787 | -1.20116 | -0.53929 |
投资活动产生的现金 | -0.01 | -0.007 | 26.176 | 40.2466 | -0.64761 |
其他投资现金流量项目,总计 | 26.176 | 40.2466 | -0.64761 | ||
融资活动产生的现金 | 32.214 | 63.456 | -25.577 | -39.4649 | 0.6825 |
融资现金流项目 | 0 | 11.05 | 0 | -0.0075 | |
股票的发行(报废),净额 | 22.712 | 53.682 | -26.2972 | -40.7267 | 0 |
债务的发行(退还),净额 | 9.502 | -1.276 | 0.72027 | 1.26176 | 0.69 |
现金净变化 | -7.551 | 25.746 | 0.00046 | -0.01107 | -0.4383 |
Cash Taxes Paid | 0 | 0.17 | |||
经营活动产生的现金 | 0.004 | 0.002 | |||
资本支出 | -0.01 | -0.007 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -11.039 | -39.754 | -29.513 | -20.43 | -13.448 |
Cash From Operating Activities | -6.089 | -39.755 | -31.437 | -25.171 | -10.38 |
Cash From Operating Activities | 0.001 | 0.004 | 0.003 | 0.002 | 0.001 |
Non-Cash Items | 2.455 | -0.704 | -1.956 | -2.534 | -0.924 |
Changes in Working Capital | 2.494 | 0.699 | 0.029 | -2.209 | 3.991 |
Cash From Investing Activities | -0.004 | -0.01 | -0.011 | -0.006 | -0.003 |
Capital Expenditures | -0.004 | -0.01 | -0.011 | -0.006 | -0.003 |
Cash From Financing Activities | 2.545 | 32.214 | 22.092 | 22.12 | 22.98 |
Issuance (Retirement) of Stock, Net | 2.545 | 22.712 | 22.61 | 22.638 | 22.98 |
Net Change in Cash | -3.548 | -7.551 | -9.356 | -3.057 | 12.597 |
Financing Cash Flow Items | 0 | 0 | 0 | ||
Issuance (Retirement) of Debt, Net | 9.502 | -0.518 | -0.518 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Javitt (Jonathan C) | Individual Investor | 20.578 | 14468329 | 0 | 2023-04-27 | LOW |
Javitt (Daniel C) | Individual Investor | 13.7154 | 9643234 | 0 | 2023-04-27 | LOW |
Hurvitz (Chaim) | Individual Investor | 3.2818 | 2307453 | 162660 | 2023-04-27 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.1023 | 1478153 | 34990 | 2023-03-31 | LOW |
Willard (Stephen H) | Individual Investor | 1.4934 | 1050000 | 0 | 2023-04-27 | LOW |
Flynn (Patrick John) | Individual Investor | 1.071 | 752996 | 162660 | 2023-04-27 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5386 | 378667 | 0 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.5242 | 368598 | 2718 | 2023-03-31 | LOW |
Bridgeway Capital Management, LLC | Investment Advisor | 0.3281 | 230700 | 52000 | 2023-03-31 | |
Gorovitz (Aaron) | Individual Investor | 0.2906 | 204346 | 162660 | 2023-04-27 | MED |
Glied (Sharon A) | Individual Investor | 0.2501 | 175828 | 162660 | 2023-04-27 | MED |
Besthof (Robert) | Individual Investor | 0.233 | 163827 | 140117 | 2023-04-27 | MED |
Orfeo Capital SGIIC SA | Investment Advisor | 0.1841 | 129449 | 117224 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.1625 | 114240 | 0 | 2023-03-31 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.1147 | 80623 | 52895 | 2023-03-31 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1013 | 71241 | 12643 | 2023-03-31 | LOW |
Texas Capital Bank Private Wealth Advisors | Investment Advisor | 0.09 | 63290 | 0 | 2023-03-31 | LOW |
HBKS Wealth Advisors | Investment Advisor | 0.0831 | 58460 | 58460 | 2022-12-31 | MED |
Van Voorhees (Seth L) | Individual Investor | 0.0659 | 46337 | 0 | 2023-04-27 | HIGH |
Virtu Americas LLC | Research Firm | 0.0657 | 46210 | 46210 | 2023-03-31 | HIGH |
交易计算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
- 1:1
- 20
- 100
- 500
- 1000
- 10000
NRx Pharmaceuticals, Inc. Company profile
关于 NRx Pharmaceuticals Inc.
NRX Pharmaceuticals, Inc.的前身是Big Rock Partners Acquisition Corp.,是一家以病人为中心的临床阶段制药公司。 该公司专注于开发NRX-101。 NRX-101是一种治疗双相情感障碍的急性自杀行为/痴呆的口服治疗药物,以及治疗COVID-19呼吸衰竭的静脉注射和吸入药物ZYESAMI (aviptadil)。 NRX-101旨在提供一种口服、快速发作和持续的家庭使用疗法,可以延长氯胺酮的抗自杀益处,并减少氯胺酮的副作用。 公司将D-环丝氨酸(DCS)(一种N-甲基-D-天门冬氨酸(NMDA)受体调节剂)和鲁拉西酮(一种5-HT2a受体拮抗剂)相结合。 NRX-101正处于临床测试的第三阶段。
Industry: | Biotechnology & Medical Research (NEC) |
1201 Orange Street
Suite 600
WILMINGTON
DELAWARE 19801
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球535,000万多名交易者的一份子,选择利用Capital.com进行交易吧。